WO2024257023A8 - Ligands de pseudokinase tyk2 et leurs utilisations - Google Patents

Ligands de pseudokinase tyk2 et leurs utilisations Download PDF

Info

Publication number
WO2024257023A8
WO2024257023A8 PCT/IB2024/055815 IB2024055815W WO2024257023A8 WO 2024257023 A8 WO2024257023 A8 WO 2024257023A8 IB 2024055815 W IB2024055815 W IB 2024055815W WO 2024257023 A8 WO2024257023 A8 WO 2024257023A8
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
tyk2
ligands
tyk2 pseudokinase
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2024/055815
Other languages
English (en)
Other versions
WO2024257023A1 (fr
Inventor
Suresh KURHADE
Garima PRIYADARSHANI
Shailendra SISODIYA
Mahesh HALLE
Jeevak Sopanrao KAPURE
Jissy Akkarapattiakal KURIAPPAN
Sanchari Basu MALLIK
Amol TANDON
Ganesan Subramaniam
Abishek Venkatasubramanian IYER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alembic Pharmaceuticals Ltd
Original Assignee
Alembic Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Pharmaceuticals Ltd filed Critical Alembic Pharmaceuticals Ltd
Publication of WO2024257023A1 publication Critical patent/WO2024257023A1/fr
Publication of WO2024257023A8 publication Critical patent/WO2024257023A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés de formule A qui sont utiles dans la modulation de l'inflammation et le traitement de troubles associés par action sur TYK2 pour provoquer une inhibition de la transduction de signal médiée par TYK2. Dans certains modes de réalisation, le trouble médié par TYK2 est un trouble auto-immun, un trouble inflammatoire, un trouble endocrinien, un trouble neurologique, un trouble prolifératif ou un trouble associé à une transplantation.
PCT/IB2024/055815 2023-06-14 2024-06-14 Ligands de pseudokinase tyk2 et leurs utilisations Ceased WO2024257023A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202321040658 2023-06-14
IN202321040658 2023-06-14

Publications (2)

Publication Number Publication Date
WO2024257023A1 WO2024257023A1 (fr) 2024-12-19
WO2024257023A8 true WO2024257023A8 (fr) 2025-01-16

Family

ID=91699945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/055815 Ceased WO2024257023A1 (fr) 2023-06-14 2024-06-14 Ligands de pseudokinase tyk2 et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2024257023A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013341186B2 (en) 2012-11-08 2017-03-30 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
CA2890935A1 (fr) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composes de pyrimidine a substitution d'amide alkyl utiles pour la modulation des il-12, il 23 et ifn.alpha
HRP20250048T1 (hr) * 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN116262739A (zh) * 2021-12-13 2023-06-16 上海翰森生物医药科技有限公司 含氮芳基衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
WO2024257023A1 (fr) 2024-12-19

Similar Documents

Publication Publication Date Title
EP4461734A3 (fr) Inhibiteurs de tyk2 et leurs utilisations
Vella et al. Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection
ES423728A1 (es) Un sistema para transferir senales de audio de banda ancha.
GB1531092A (en) Carboxylic esters of substituted p-phenyl phenols and their use in liquid crystal cells
CA2135083A1 (fr) Anticorps de la p-selectine et leur utilite
MY111084A (en) One-bit analog-to-digital converters and digital-to- analog converters using an adaptive filter having two regimers of operation
MX2024011231A (es) Inhibidores de tyk2 y usos de los mismos
ES425706A1 (es) Perfeccionamientos en el montaje de los conjuntos de husos en una maquina de procesado de hilatura textil.
US4151516A (en) PCM coder with shifting idle channel noise level
WO2002002097A3 (fr) Procédé pour traiter les troubles à crises par inhibition de l'activation du canal mapk
GB1074438A (en) Improvements in or relating to disc cam devices
GB191200201A (en) Improvements in Back-sights for Automatic Pistols and other Small-Arms.
SU398682A1 (ru) Износостойкий сплав на основе жел
FI942989A0 (fi) Isomerointimenetelmä
Vitkevich et al. Dynamic spectra and principal characteristics of short-lived bursts of solar radio emission
AR131375A1 (es) Ligandos de pseudoquinasa tyk2 y sus usos
GB191229760A (en) Improved Means for use in Substitution for a Gib and Cotter or like Fastening.
WO2024059212A3 (fr) Composés à noyau 6,6 western servant de modulateurs allostériques négatifs de mglu5 et leurs procédés de production et d'utilisation
GB246728A (en) Improvements in electrostatic telephones
WO2024059210A3 (fr) Composés à noyau 6,5 western utilisés en tant que modulateurs allostériques négatifs du mglu5 et leurs méthodes de production et d'utilisation
JPS5745720A (en) Quantizing circuit
GB190628277A (en) An Improvement relating to the Construction of Expansible Pulleys.
FR2229155A1 (en) Fixture for aerial telecommunication cable supports - consisting of interlocking hard half-rings to increase bearing-surface
GB579922A (en) Improvements in or relating to controlling cams, more particularly adapted for controlling the fuel pumps of reversible internal-combustion engines
FR3042928A1 (fr) Dispositif de generation de signaux analogiques et utilisation associee

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24736861

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE